Sec Form 13G Filing - ARCH Venture Fund VII L.P. filing for Unity Biotechnology Inc. (UBX) - 2022-02-11

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

  (Amendment No. 3)*

 

 

Unity Biotechnology, Inc.

(Name of Issuer)

   

Common Stock par value $0.0001 per share

(Title of Class of Securities)

  

91381U101

(CUSIP Number)

  

December 31, 2021

(Date of Event Which Requires Filing of This Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐   Rule 13d-1(b)

☐   Rule 13d-1(c)

☒   Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.  91381U101

13G

Page 2 of 17 Pages

 

CUSIP No.  91381U101

13G

Page 3 of 17 Pages

 

CUSIP No.  91381U101

13G

Page 4 of 17 Pages

 

CUSIP No.  91381U101

13G

Page 5 of 17 Pages

 

CUSIP No.  91381U101

13G

Page 6 of 17 Pages

 

CUSIP No.  91381U101

13G

Page 7 of 17 Pages

 

CUSIP No.  91381U101

13G

Page 8 of 17 Pages

 

CUSIP No.  91381U101

13G

Page 9 of 17 Pages

 

CUSIP No.  91381U101

13G

Page 10 of 17 Pages

 

 

Item 1(a).

Name of Issuer:

 

Unity Biotechnology, Inc. (the “Issuer”).

 

 

Item 1(b).

Address of Issuer's Principal Executive Offices:

 

285 East Grand Ave. South, San Francisco, CA 94080

 

 

Item 2(a).

Name of Person Filing:

 

ARCH Venture Fund VII, L.P. (“ARCH Venture Fund VII”); ARCH Venture Fund VIII Overage, L.P. (“AVF VIII Overage LP”); ARCH Venture Partners VII, L.P. (“AVP VII LP”); ARCH Venture Partners VII, LLC (“AVP VII LLC”); ARCH Venture Partners VIII, LLC (“AVP VIII LLC”) (collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”) and Clinton Bybee (“Bybee”) (collectively, the “Managing Directors” and individually, each a “Managing Director”). The Reporting Entities and the Managing Directors collectively are referred to as the “Reporting Persons”. 

 

 

Item 2(b).

Address of Principal Business Office or, if none, Residence:

 

8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631

 

 

Item 2(c).

Citizenship:

 

ARCH Venture Fund VII, AVF VIII Overage LP and AVP VIII LP are limited partnerships organized under the laws of the State of Delaware. AVP VII LLC and AVP VIII LLC are limited liability companies organized under the laws of the State of Delaware. Each Managing Director is a US citizen.

 

 

Item 2(d).

Title of Class of Securities.

 

Common stock, par value $0.0001 per share.

 

 

Item 2(e).

CUSIP Number.

 

91381U101

 

  

Item 3.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

 

Not Applicable.

 

CUSIP No.  91381U101

13G

Page 11 of 17 Pages

 

Item 4.

Ownership:

 

(a)	Amount beneficially owned:   ARCH Venture Fund VII is the record owner of 8,365,764 shares of Common Stock (the “ARCH VII Shares”) as of December 31, 2021. AVP VII LP, as the sole general partner of ARCH Venture Fund VII, may be deemed to beneficially own the ARCH VII Shares. AVP VII LLC, as the sole general partner of AVP VII LP, may be deemed to beneficially own ARCH VII Shares. AVF VIII Overage LP is the record owner of 1,682,417 shares of Common Stock (the “Overage Shares”; combined with ARCH VII Shares, the “Record Shares”) as of December 31, 2021. AVP VIII LLC, as the sole general partner of AVF VIII Overage LP, may be deemed to beneficially own the Overage Shares. As managing directors of AVP VII LLC and AVP VIII LLC, each Managing Director may also be deemed to share the power to direct the disposition and vote of the Record Shares. In addition, as of December 31, 2021, Nelsen is a holder of vested options to purchase 90,678 shares of Common Stock (the “Vested Option Shares”).
(b)	Percent of class:   See line 11 of the cover sheets. The percentages set forth on the cover sheet for each Reporting Person (other than Nelsen) is based upon 57,724,179 shares of common stock outstanding as of November 5, 2021 as reported on the Issuers Form 10-Q as filed with the Securities and Exchange Commission on November 10, 2021. For Nelsen, the Vested Option Shares were included in the number of shares of Common stock outstanding.
(c)	Number of shares as to which such person has:

	(i)	Sole power to vote or to direct the vote:   See line 5 of the cover sheets.
	(ii)	Shared power to vote or to direct the vote:   See line 6 of the cover sheets.
	(iii)	Sole power to dispose or to direct the disposition:   See line 7 of the cover sheets.
	(iv)	Shared power to dispose or to direct the disposition:   See line 8 of the cover sheets.

Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.

 

Item 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

 

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not applicable.

 

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable.

 

 

Item 9.

Notice of Dissolution of Group.

 

Not applicable.

 

 

Item 10.

Certifications.

 

Not applicable.

CUSIP No.  91381U101

13G

Page 12 of 17 Pages

 

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated:    February 11, 2022

ARCH VENTURE FUND VII, L.P.

 

By:       ARCH Venture Partners VII, L.P.

its General Partner

 

By:       ARCH Venture Partners VII, LLC

its General Partner

 

By:                        *               

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VII, L.P.

 

By:       ARCH Venture Partners VII, LLC

its General Partner

 

By:                               *                    

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VII, LLC

 

By:                               *                                

Keith Crandell

Managing Director

 

 

                                      *                        &# xA0;        

Keith Crandell

 

 

                                      *                                 

Robert Nelsen

 

 

                                      *                                 

Clinton Bybee

 

 

 

 

 

 

 

CUSIP No.  91381U101

13G

Page 13 of 17 Pages

 

 

 

 

ARCH VENTURE FUND VIII OVERAGE, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:                            *                       

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, LLC

 

By:                                *                               

Keith Crandell

Managing Director

 

 

 

 

 

 

* By:   /s/ Mark McDonnell                  

Mark McDonnell as

Attorney-in-Fact

 

 

This Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2.0 and Exhibit 2.1 and incorporated herein by reference.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CUSIP No.  91381U101

13G

Page 14 of 17 Pages

 

 

Exhibit 1

 

AGREEMENT

 

Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Unity Biotechnology, Inc.

 

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

 

 

Dated:    February 11, 2022

ARCH VENTURE FUND VII, L.P.

 

By:       ARCH Venture Partners VII, L.P.

its General Partner

 

By:       ARCH Venture Partners VII, LLC

its General Partner

 

By:                     *                 

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VII, L.P.

 

By:       ARCH Venture Partners VII, LLC

its General Partner

 

By:                            *                       

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VII, LLC

 

By:                               *                                

Keith Crandell

Managing Director

 

 

                                      *                                 

Keith Crandell

 

 

                                      *                                 

Robert Nelsen

 

 

                                      *                                 

Clinton Bybee

 

 

 

 

 

 

 

CUSIP No.  91381U101

13G

Page 15 of 17 Pages

 

 

 

 

ARCH VENTURE FUND VIII OVERAGE, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:                           *                        

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, LLC

 

By:                            *                                   

Keith Crandell

Managing Director

 

 

 

 

 

 

* By:   /s/ Mark McDonnell                  

Mark McDonnell as

Attorney-in-Fact

 

 

This Agreement was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2.0 and Exhibit 2.1 and incorporated herein by reference.

 

 

 

 

 

 

 

 

 

 

 

< p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> 

CUSIP No.  91381U101

13G

Page 16 of 17 Pages

Exhibit 2.0

 

POWERS OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, member, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney shall remain in full force and effect with respect to each undersigned person unless and until six months after such person is both no longer a Managing Director of ARCH Venture Partners and no longer serving on the board of directors of any portfolio company of any ARCH Venture Partners fund.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 7^th day of May 2013.

 

ARCH VENTURE FUND VII, L.P.

 

By:       ARCH Venture Partners VII, L.P.

its General Partner

 

By:       ARCH Venture Partners VII, LLC

its General Partner

 

By:    /s/ Keith Crandell      

Managing Director

 

 

ARCH VENTURE PARTNERS VII, L.P.

 

By:       ARCH Venture Partners VII, LLC

its General Partner

 

By:   /s/ Keith Crandell                    

Managing Director

 

 

ARCH VENTURE PARTNERS VII, LLC

 

By:        /s/ Keith Crandell                            

Managing Director

 

  

/s/ Keith Crandell                                          

Keith Crandell

 

 

/s/ Robert Nelsen                                          

Robert Nelsen

 

 

/s/ Clinton Bybee                                          

Clinton Bybee

 

 

/s/ Kristina Burow                                         

Kristina Burow

 

 

/s/ Paul Thurk                                                 

Paul Thurk

 

CUSIP No.  91381U101

13G

Page 17 of 17 Pages

Exhibit 2.1

 

 

POWERS OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, member, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Com mission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney shall remain in full force and effect with respect to each undersigned person unless and until six months after such person is both no longer a Managing Director of ARCH Venture Partners and no longer serving on the board of directors of any portfolio company of any ARCH Venture Partners fund.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 26^th day of July, 2017.

 

 

ARCH VENTURE FUND VIII OVERAGE, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:   /s/ Keith Crandell               

Managing Director

 

 

ARCH VENTURE PARTNERS VIII, L.P.

 

By:       ARCH Venture Partners VIII, LLC

its General Partner

 

By:   /s/ Keith Crandell               

Managing Director